Zydus Lifesciences
Update in progressZYDUSLIFE.NS (NSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Zydus Lifesciences Limited conducts R&D, manufacturing, marketing, distribution and sale of pharmaceutical products in India, the United States and globally. It operates in Pharmaceuticals and Consumer Products, offering APIs, finished dosage forms, generics, biosimilars, vaccines and consumer brands such as Everyuth, Nutralite, SugarFree, Complan, Glucon‑D and Nycil. It also develops biologics for oncology, autoimmune, nephrology, inflammation and infections, plus orthopaedics. Formerly Cadila Healthcare, renamed 2022. Founded 1952, based in Ahmedabad, India; part of Zydus Family Trust.
Company score
- Sentiment
- 2.23
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.01
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 2.00
- Governance
- 0.49
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.70
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.47
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!